Recursive Language Models aim to break the usual trade off between context length, accuracy and cost in large language models. Instead of forcing a model to read a giant prompt in one pass, RLMs treat ...

There is a surge of interest in career and technical education programs at the secondary school level, fueled by concerns about the cost of college and opportunities to make good money in jobs that ...

Abstract: The recursive least-squares (RLS) algorithm is very popular for adaptive filtering applications, mainly due to its fast convergence rate. The regularized version of this algorithm owns ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Students are increasingly interested in focusing on digital technology, information technology, artificial intelligence, and cybersecurity in their career and technical education courses, according to ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

With the official release of Microsoft's latest database offering, let's see what was improved and what still needs some work. Today, at Ignite, Microsoft announced the general availability of SQL ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

This story mentions suicide. Mental health resources can be found at the bottom of this story. The death of Dallas Cowboys defensive end Marshawn Kneeland from an apparent self-inflicted gunshot wound ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...